Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogs

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Bisphosphonates (BPs) have been shown to significantly reduce bone toughness in vertebrae within one year when given at clinical doses to dogs. Although BPs also reduce toughness in the cortical bone when given at high doses, their effect on cortical bone material properties when given at clinical doses is less clear. In part, this may be due to the use of small sample sizes that were powered to demonstrate differences in bone mineral density rather than the bone's material properties. Our lab has conducted several studies in which dogs were treated with alendronate at a clinically relevant dose. The goal of this study was to examine these published and unpublished data collectively to determine whether there is a significant time-dependent effect of alendronate on toughness of the cortical bone. This analysis seemed particularly relevant given the recent occurrence of atypical femoral fractures in humans. Differences in the toughness of ribs taken from dogs derived from five separate experiments were measured. The dogs were orally administered saline (CON, 1. ml/kg/day) or alendronate (ALN) at a clinical dose (0.2. mg/kg/day). Treatment duration ranged from 3. months to 3. years. Groups were compared using ANOVA, and time trends analyzed with linear regression analysis. Linear regressions of the percent difference in toughness between CON and ALN at each time point revealed a significant reduction in toughness with longer exposure to ALN. The downward trend was primarily driven by a downward trend in post-yield toughness, whereas toughness in the pre-yield region was not changed relative to CON. These data suggest that a longer duration of treatment with clinical doses of ALN results in deterioration of cortical bone toughness in a time-dependent manner. As the duration of treatment is lengthened, the cortical bone exhibits increasingly brittle behavior. This may be important in assessing the role that long-term BP treatments play in the risk of atypical fractures of the femoral cortical bone in humans.

Original languageEnglish
Pages (from-to)58-62
Number of pages5
JournalBone
Volume71
DOIs
StatePublished - Feb 1 2015

Fingerprint

Alendronate
Dogs
Diphosphonates
Femoral Fractures
Linear Models
Bone and Bones
Ribs
Sample Size
Bone Density
Cortical Bone
Analysis of Variance
Spine
Regression Analysis

Keywords

  • Atypical femoral fractures
  • Bisphosphonates
  • Cortical bone
  • Toughness

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogs. / Burr, David; Liu, Ziyue; Allen, Matthew.

In: Bone, Vol. 71, 01.02.2015, p. 58-62.

Research output: Contribution to journalArticle

@article{e79831d404114facaa9f426f657bc83e,
title = "Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogs",
abstract = "Bisphosphonates (BPs) have been shown to significantly reduce bone toughness in vertebrae within one year when given at clinical doses to dogs. Although BPs also reduce toughness in the cortical bone when given at high doses, their effect on cortical bone material properties when given at clinical doses is less clear. In part, this may be due to the use of small sample sizes that were powered to demonstrate differences in bone mineral density rather than the bone's material properties. Our lab has conducted several studies in which dogs were treated with alendronate at a clinically relevant dose. The goal of this study was to examine these published and unpublished data collectively to determine whether there is a significant time-dependent effect of alendronate on toughness of the cortical bone. This analysis seemed particularly relevant given the recent occurrence of atypical femoral fractures in humans. Differences in the toughness of ribs taken from dogs derived from five separate experiments were measured. The dogs were orally administered saline (CON, 1. ml/kg/day) or alendronate (ALN) at a clinical dose (0.2. mg/kg/day). Treatment duration ranged from 3. months to 3. years. Groups were compared using ANOVA, and time trends analyzed with linear regression analysis. Linear regressions of the percent difference in toughness between CON and ALN at each time point revealed a significant reduction in toughness with longer exposure to ALN. The downward trend was primarily driven by a downward trend in post-yield toughness, whereas toughness in the pre-yield region was not changed relative to CON. These data suggest that a longer duration of treatment with clinical doses of ALN results in deterioration of cortical bone toughness in a time-dependent manner. As the duration of treatment is lengthened, the cortical bone exhibits increasingly brittle behavior. This may be important in assessing the role that long-term BP treatments play in the risk of atypical fractures of the femoral cortical bone in humans.",
keywords = "Atypical femoral fractures, Bisphosphonates, Cortical bone, Toughness",
author = "David Burr and Ziyue Liu and Matthew Allen",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.bone.2014.10.010",
language = "English",
volume = "71",
pages = "58--62",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogs

AU - Burr, David

AU - Liu, Ziyue

AU - Allen, Matthew

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Bisphosphonates (BPs) have been shown to significantly reduce bone toughness in vertebrae within one year when given at clinical doses to dogs. Although BPs also reduce toughness in the cortical bone when given at high doses, their effect on cortical bone material properties when given at clinical doses is less clear. In part, this may be due to the use of small sample sizes that were powered to demonstrate differences in bone mineral density rather than the bone's material properties. Our lab has conducted several studies in which dogs were treated with alendronate at a clinically relevant dose. The goal of this study was to examine these published and unpublished data collectively to determine whether there is a significant time-dependent effect of alendronate on toughness of the cortical bone. This analysis seemed particularly relevant given the recent occurrence of atypical femoral fractures in humans. Differences in the toughness of ribs taken from dogs derived from five separate experiments were measured. The dogs were orally administered saline (CON, 1. ml/kg/day) or alendronate (ALN) at a clinical dose (0.2. mg/kg/day). Treatment duration ranged from 3. months to 3. years. Groups were compared using ANOVA, and time trends analyzed with linear regression analysis. Linear regressions of the percent difference in toughness between CON and ALN at each time point revealed a significant reduction in toughness with longer exposure to ALN. The downward trend was primarily driven by a downward trend in post-yield toughness, whereas toughness in the pre-yield region was not changed relative to CON. These data suggest that a longer duration of treatment with clinical doses of ALN results in deterioration of cortical bone toughness in a time-dependent manner. As the duration of treatment is lengthened, the cortical bone exhibits increasingly brittle behavior. This may be important in assessing the role that long-term BP treatments play in the risk of atypical fractures of the femoral cortical bone in humans.

AB - Bisphosphonates (BPs) have been shown to significantly reduce bone toughness in vertebrae within one year when given at clinical doses to dogs. Although BPs also reduce toughness in the cortical bone when given at high doses, their effect on cortical bone material properties when given at clinical doses is less clear. In part, this may be due to the use of small sample sizes that were powered to demonstrate differences in bone mineral density rather than the bone's material properties. Our lab has conducted several studies in which dogs were treated with alendronate at a clinically relevant dose. The goal of this study was to examine these published and unpublished data collectively to determine whether there is a significant time-dependent effect of alendronate on toughness of the cortical bone. This analysis seemed particularly relevant given the recent occurrence of atypical femoral fractures in humans. Differences in the toughness of ribs taken from dogs derived from five separate experiments were measured. The dogs were orally administered saline (CON, 1. ml/kg/day) or alendronate (ALN) at a clinical dose (0.2. mg/kg/day). Treatment duration ranged from 3. months to 3. years. Groups were compared using ANOVA, and time trends analyzed with linear regression analysis. Linear regressions of the percent difference in toughness between CON and ALN at each time point revealed a significant reduction in toughness with longer exposure to ALN. The downward trend was primarily driven by a downward trend in post-yield toughness, whereas toughness in the pre-yield region was not changed relative to CON. These data suggest that a longer duration of treatment with clinical doses of ALN results in deterioration of cortical bone toughness in a time-dependent manner. As the duration of treatment is lengthened, the cortical bone exhibits increasingly brittle behavior. This may be important in assessing the role that long-term BP treatments play in the risk of atypical fractures of the femoral cortical bone in humans.

KW - Atypical femoral fractures

KW - Bisphosphonates

KW - Cortical bone

KW - Toughness

UR - http://www.scopus.com/inward/record.url?scp=84908637567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908637567&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2014.10.010

DO - 10.1016/j.bone.2014.10.010

M3 - Article

C2 - 25445446

AN - SCOPUS:84908637567

VL - 71

SP - 58

EP - 62

JO - Bone

JF - Bone

SN - 8756-3282

ER -